Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

If passed, ALS research funding continues uninterrupted through 2031, preventing research program gaps. The clinical trial data monitoring requirement gives the FDA visibility into enrollment progress, potentially flagging underpowered studies early—a lesson from past rare disease programs where small patient populations created enrollment bottlenecks. Expanding FDA coordination to non-ALS rare neurodegeneration communities may accelerate therapy development for diseases like frontotemporal dementia and primary progressive MS, but could also spread limited FDA resources across a broader disease portfolio. The GAO report requirement (4 years out) provides accountability but comes after 2+ years of expanded operations, limiting real-time course correction. Analogous precedent: the 21st Century Cures Act accelerated FDA pathways for rare disease drugs starting 2016; studies show breakthrough designation reduced review times by 4-6 months on average but did not increase approval rates for ineffective drugs—suggesting the monitoring requirement in this bill addresses legitimate oversight gaps.